Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 15, 2013 05:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders

NEW YORK, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) ("Synergy") today announced that it convened its annual meeting of stockholders yesterday and it has received the...
January 03, 2013 16:30 ET | Source: Synergy Pharmaceuticals

Synergy Announces Adjournment of Annual Meeting

NEW YORK, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that it convened its annual meeting of stockholders on Thursday, January 3, 2013 and adjourned...
January 02, 2013 05:00 ET | Source: Synergy Pharmaceuticals

Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation

Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide,...
December 28, 2012 05:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases

NEW YORK, Dec. 28, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the successful...
December 27, 2012 05:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)

NEW YORK, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has...
December 14, 2012 08:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

NEW YORK, Dec. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that a poster...
November 21, 2012 08:50 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

NEW YORK, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President...
November 13, 2012 16:31 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Reports Third Quarter 2012 Financial Results

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results...
November 09, 2012 17:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Announces Extension for Filing of Third Quarter Form 10-Q Due to Hurricane Sandy

NEW YORK, Nov. 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that, in accordance...
October 22, 2012 17:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation

NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the preclinical...